1-9 of 9
Monique Dail, PhD
Close
Sort by
Journal Articles

Assessment of Minimal Residual Disease By Next-Generation Sequencing and Fluorodeoxyglucose-Positron Emission Tomography in Patients with Relapsed/Refractory Multiple Myeloma Treated with Venetoclax in Combination with Carfilzomib and Dexamethasone

Luciano J. Costa, MD PhD, Nicholas Burwick, MD, Andrzej Jakubowiak, MD PhD, Jonathan L. Kaufman, MD, Fernando Cabanillas, MD, Monique Dail, PhD, Sudeep Karve, Abdullah A. Masud, PhD, Xiaoqing Yang, PhD, Orlando F. Bueno, Sarah Mudd, PhD, Jeremy A. Ross, Faith E. Davies
Journal: Blood
Blood (2020) 136 (Supplement 1): 4–5.
https://doi.org/10.1182/blood-2020-134737
Published: 2020
Journal Articles

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 Mutations

Daniel A. Pollyea, Courtney D. Dinardo, MDMSc, Martha L. Arellano, MD, Arnaud Pigneux, MD PhD, Walter Fiedler, MD, Marina Konopleva, MD PhD, David A Rizzieri, MD, B. Douglas Smith, MD, Atsushi Shinagawa, MD PhD, Roberto M. Lemoli, Monique Dail, PhD, Yinghui Duan, PhD, Brenda J. Chyla, Jalaja Potluri, MD, Jean A Ridgeway, DNP, NP-C, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 5–7.
https://doi.org/10.1182/blood-2020-134736
Published: 2020
Journal Articles

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations

Marina Konopleva, MD PhD, Michael Thirman, MD, Keith W. Pratz, MD, Anthony G. Letai, MD PhD, Christian Recher, MD PhD, Vinod A. Pullarkat, MD, Hagop M. Kantarjian, MD, Monique Dail, PhD, Yinghui Duan, PhD, Brenda J. Chyla, Jalaja Potluri, MD, Catherine Miller, PharmD, Courtney D. Dinardo, MDMSc, Andrew H. Wei, MBBS, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 8–10.
https://doi.org/10.1182/blood-2020-134100
Published: 2020
Journal Articles

Integrative Analysis of the Genomic and Transcriptomic Landscape of Relapsed/Refractory Multiple Myeloma Patients Treated With Venetoclax in Combination With Bortezomib and Dexamethasone: Biomarker Analyses From the Phase 3 BELLINI Study

Michael E. O'Dwyer, MD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Shaji K. Kumar, MD, Rakesh Popat, Philippe Moreau, MD, Monique Dail, PhD, Muhammad Jalaluddin, PhD, Xiaoqing Yang, PhD, Xin Lu, Zheng Zha, Fengjiao Dunbar, PhD, Deeksha Vishwamitra, PhD, Christine Mantis, PhD, Amal Melhem-Bertrandt, MD, Jeremy A. Ross, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-134710
Published: 2020
Journal Articles

Response to Venetoclax in Combination with Low Intensity Therapy (LDAC or HMA) in Untreated Patients with Acute Myeloid Leukemia Patients with IDH, FLT3 and Other Mutations and Correlations with BCL2 Family Expression

Brenda J Chyla, PhD, Jason Harb, PhD, Christine Mantis, PhD, Jacob J Riehm, PhD, Jeremy A. Ross, PhD, Yan Sun, PhD, Xin Huang, PhD MD, Qi Jiang, PhD, Monique Dail, PhD, Franklin V. Peale, Jr., MD PhD, Jalaja Potluri, MD, John Hayslip
Journal: Blood
Blood (2019) 134 (Supplement_1): 546.
https://doi.org/10.1182/blood-2019-128373
Published: 2019
Journal Articles

Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy

Naval G. Daver, MD, Jacqueline S Garcia, MD, Brian A Jonas, MD PhD, Kevin R Kelly, MD PhD, Sarit Assouline, MD, Joseph M Brandwein, MD, Pierre Fenaux, MD PhD, Rebecca L. Olin, MD, Giovanni Martinelli, MD, Stefania Paolini, MD PhD, Arnaud Pigneux, Daniel A Pollyea, MD, Bayard L Powell, MD, Gail J. Roboz, MD, Agostino Tafuri, MD, Norbert Vey, MD PhD, Giuseppe Visani, MD, Karen W.L. Yee, MD, Monique Dail, PhD, Cherie Green, BS, Whitney P Kirschbrown, PharmD, PhD, Wan-Jen Hong, MD, Marion G Ott, MD PhD, Maika Onishi, MD, Jue Wang, PhD, Marina Y Konopleva, MD PhD, Michael Andreeff, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 229.
https://doi.org/10.1182/blood-2019-123711
Published: 2019
Journal Articles

Preclinical Testing Of a PI3K Inhibitor In T Lineage Leukemia: Target Validation and Notch1/Myc Down-Regulation In Drug Resistant Clones

Monique Dail, PhD, Jason Wong, Jessica Lawrence, Daniel O'Connor, Joy Nakitandwe, PhD., Shann-Ching Chen, PhD, Keiko Akagi, Leslie Lee, Jon C. Aster, MD, PhD, Warren S. Pear, MD, PhD, Deepak Sampath, PhD, James R. Downing, MD, Kevin Shannon, MD
Journal: Blood
Blood (2013) 122 (21): 2677.
https://doi.org/10.1182/blood.V122.21.2677.2677
Published: 2013
Journal Articles

The PI3K Inhibitor GDC-0941 Attenuates Disease in a Kras G12D Mouse Model of CMML and JMML.

Jon Akutagawa, B.S., Monique Dail, PhD, Lori S Friedman, PhD, Kevin M. Shannon, MD, Deepak Sampath, PhD, Benjamin S. Braun, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 2862.
https://doi.org/10.1182/blood.V120.21.2862.2862
Published: 2012
Journal Articles

Kras G12D Expression in Hematopoietic Stem/Progenitor Cells Initiates T Cell Acute Lymphoblastic Leukemia/Lymphoma.

Monique Dail, PhD, Qing Li, MD, PhD, Jennifer Lauchle, MD, Andrew McDaniel, Doris Kim, Keiko Akagi, PhD, Linda Wolff, PhD, Nancy Jenkins, PhD, Neil Copeland, PhD, Kevin Shannon, MD
Journal: Blood
Blood (2007) 110 (11): 153.
https://doi.org/10.1182/blood.V110.11.153.153
Published: 2007